|
GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered … GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adults GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News